Solu-Cortef Shortage Update: What Patients Need to Know in 2026

Solu-Cortef (hydrocortisone sodium succinate for injection) has experienced multiple supply disruptions since 2023, leaving patients with adrenal insufficiency and other serious conditions worried about access to this critical medication. This article provides the most current shortage update for 2026 and actionable guidance for patients navigating the supply landscape.

Is Solu-Cortef Currently in Shortage in 2026?

Short answer: No active FDA shortage as of early 2026. As of October 2025, the American Society of Health-System Pharmacists (ASHP) confirmed that "Pfizer has all Solu-Cortef presentations available." The shortage detail that was created in March 2023 remains on the ASHP database for historical tracking, but active shortage status has been resolved.

However, "no active shortage" does not mean every pharmacy has it in stock. Localized availability gaps still occur — particularly for the 100 mg/2 mL ACT-O-VIAL home emergency kit that adrenal insufficiency patients rely on for self-injection during an adrenal crisis.

Shortage Timeline: What Happened and When

March 2023: Pfizer announced a supply disruption for Solu-Cortef 100 mg/2 mL ACT-O-VIAL Single Dose Vials. Disruption was caused by quality control issues and increased demand. Pfizer restricted distribution to direct institutional orders only, allocating limited quantities to facilities with documented purchase history.

May 2023: FDA issued an emergency date extension for 32 lots of Solu-Cortef — extending expiry by five months beyond the labeled 36-month expiration date. This measure helped stretch available inventory.

Late 2023: Estimated recovery date reached (December 2023). Supply began to gradually normalize, though distribution remained tight.

April 2025: A second supply interruption — this time affecting the 25-pack presentation of the 100 mg/2 mL ACT-O-VIAL — was announced by Pfizer. The cause was increased demand and a manufacturing delay that Pfizer said had been resolved. Estimated recovery: Q3 2025. FDA was notified.

October 2025: ASHP confirms Pfizer has all presentations available. Shortage status updated to resolved in the U.S.

Why Do Solu-Cortef Shortages Keep Happening?

Research shows that approximately 64% of drug shortages originate from quality problems at manufacturing facilities. For Solu-Cortef, the combination of complex sterile injectable manufacturing, reliance on a single dominant brand manufacturer (Pfizer), and periodic demand surges creates vulnerability. The FDA and hospital pharmacists track these trends, but prevention remains a systemic challenge.

Who Is Most at Risk During a Solu-Cortef Shortage?

Patients who depend on home emergency kits are the most critically affected. These include:

Adrenal insufficiency / Addison's disease patients: Need the ACT-O-VIAL home kit for life-saving emergency self-injection during adrenal crisis

Congenital adrenal hyperplasia (CAH) patients: Also require stress-dose hydrocortisone during illness or injury

Pediatric endocrinology patients: Children with adrenal conditions require weight-based dosing using the same formulation

What Should Patients Do Right Now?

Check your current supply. Review expiration dates on any home emergency kits. Do not rely on expired kits.

Start refill efforts early. Begin looking for Solu-Cortef 2-3 weeks before you need it, not the day you run out.

Contact your endocrinologist or prescriber. They can route prescriptions through hospital pharmacies or specialty pharmacies with better access.

Ask about A-Hydrocort. The generic equivalent may be available when the Solu-Cortef brand is not.

Use medfinder. medfinder calls pharmacies near you to check stock, saving you time and frustration.

Where to Monitor Shortage Status

For the most current shortage information, check:

ASHP Drug Shortage Database (ashp.org/drug-shortages) — updated by pharmacist specialists

FDA Drug Shortages Database (accessdata.fda.gov) — official FDA tracking

Pfizer Hospital Availability Report (PfizerHospitalUS.com) — updated frequently by the manufacturer

The Bottom Line for Solu-Cortef Patients in 2026

The good news: supply has normalized as of late 2025 and no active national shortage is in place. The cautionary note: Solu-Cortef has proven vulnerable to recurring disruptions, and proactive planning remains essential. Use resources like medfinder to stay ahead of any localized gaps, and keep your care team updated on your supply status.

If you need a backup plan, read our guide on alternatives to Solu-Cortef if you can't fill your prescription.